Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at Least 2 Doses
Overview
Authors
Affiliations
Background: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term persistence of immune memory following 1- or 2-dose IPV schedules.
Methods: We examined induction and maintenance of immune memory following single- vs 2-dose IPV schedules, either full-dose intramuscular or fractional-dose intradermal, in rhesus macaques. Humoral responses, bone marrow-homing antibody-secreting plasma cells, and blood-circulating/lymph node-homing memory B cells were examined longitudinally.
Results: A single dose of IPV, either full or fractional, induced binding antibodies and memory B cells in all vaccinated macaques, despite failing to induce neutralizing antibodies (NT Abs) in many of them. However, these memory B cells declined rapidly, reaching below detection in the systemic circulation by 5 months; although a low frequency of memory B cells was detectable in draining lymph nodes of some, but not all, animals. By contrast, a 2-dose vaccination schedule, either full or fractional, efficiently induced NT Abs in all animals along with bone marrow-homing plasma cells and memory B cells. These memory B cells persisted in the systemic circulation for up to 16 months, the maximum duration tested after the second dose of vaccination.
Conclusions: Two doses of IPV, regardless of whether fractional or full, are more effective than a single dose for inducing long-lasting memory B cells.
Devaux C, Pontarotti P, Levasseur A, Colson P, Raoult D Front Public Health. 2024; 11:1284337.
PMID: 38259741 PMC: 10801389. DOI: 10.3389/fpubh.2023.1284337.
Chen L, Qiu Q, Zhu Q, Li J, Xie X, Shao X Hum Vaccin Immunother. 2024; 20(1):2300156.
PMID: 38189143 PMC: 10793669. DOI: 10.1080/21645515.2023.2300156.
Sharma A, Verma H, Estivariz C, Bajracharaya L, Rai G, Shah G Lancet Microbe. 2023; 4(11):e923-e930.
PMID: 37774729 PMC: 10976347. DOI: 10.1016/S2666-5247(23)00215-X.
Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.
Van Tilbeurgh M, Lemdani K, Beignon A, Chapon C, Tchitchek N, Cheraitia L Vaccines (Basel). 2021; 9(6).
PMID: 34205932 PMC: 8226531. DOI: 10.3390/vaccines9060579.
Capeding M, Gomez-Go G, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J J Infect Dis. 2020; 226(2):308-318.
PMID: 33351072 PMC: 9400411. DOI: 10.1093/infdis/jiaa770.